Regarding FDA filing in new CTCL indication in 2017, Seattle Genetics is hoping for a label that covers all patients, regardless of positivity for CD30, though the Phase III ALCANZA study was done in biomarker expressers.
Data for Seattle Genetics Inc.'s Adectris in the Phase III ALCANZA study secure the drug's bid – expected next year – for a new indication in CD30+ cutaneous T-cell lymphoma.
Adcetris (brentuximab vedotin) is currently approved for classical Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.
Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.
IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.
The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.
